Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc.

Aclaris Therapeutics, Inc.

Advinus Therapeutics Ltd

Astellas Pharma Inc.

AstraZeneca Plc

Chipscreen Biosciences Ltd

CJ HealthCare Corp.

Concert Pharmaceuticals, Inc.

Eli Lilly and Company

Galapagos NV

Gilead Sciences, Inc.

Incyte Corporation

Nissan Chemical Industries, Ltd.

Pfizer Inc.

Portola Pharmaceuticals, Inc.

Sareum Holdings Plc

Theravance Biopharma, Inc.

Vectura Group Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) Overview 9

Therapeutics Development 10

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Products under Development by Stage of Development 10

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Products under Development by Therapy Area 11

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Products under Development by Indication 12

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Products under Development by Companies 17

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Therapeutics Assessment 24

Assessment by Monotherapy/Combination Products 24

Assessment by Mechanism of Action 25

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Companies Involved in Therapeutics Development 29

AbbVie Inc. 29

Aclaris Therapeutics, Inc. 30

Advinus Therapeutics Ltd 31

Astellas Pharma Inc. 32

AstraZeneca Plc 33

Chipscreen Biosciences Ltd 34

CJ HealthCare Corp. 35

Concert Pharmaceuticals, Inc. 36

Eli Lilly and Company 37

Galapagos NV 38

Gilead Sciences, Inc. 39

Incyte Corporation 40

Nissan Chemical Industries, Ltd. 42

Pfizer Inc. 43

Portola Pharmaceuticals, Inc. 44

Sareum Holdings Plc 45

Theravance Biopharma, Inc. 46

Vectura Group Plc 47

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Drug Profiles 48

(INCB-039110 + INCB-040093) - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ATI-50001 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ATI-50002 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

AZD-0449 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

AZD-1480 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

AZD-4205 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

baricitinib - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

cerdulatinib - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

CS-944X - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

CTP-543 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

filgotinib - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

INCB-52793 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

itacitinib adipate - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

momelotinib dihydrochloride - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

NIP-565 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

peficitinib hydrobromide - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

PF-04965842 - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

PNQ-401 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

PNQ-701 - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

ruxolitinib phosphate - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

SAR-20347 - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

Small Molecules to Inhibit Jak1 for Undisclosed Indication - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

TD-1473 - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

upadacitinib tartrate - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

VR-588 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Dormant Projects 113

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Discontinued Products 115

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Featured News & Press Releases 117

Jun 23, 2016: FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD) 117

Jun 10, 2016: New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera 117

Jun 09, 2016: Baricitinib Significantly Reduces Joint Damage Progression In Rheumatoid Arthritis In Patients Who Do Not Respond To Conventional DMARDs 118

Jun 09, 2016: Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA) 119

Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 121

Jun 07, 2016: Results Of Clinical And Patient-Reported Outcomes Data For Baricitinib In Patients With Rheumatoid Arthritis To Be Presented At Annual European Congress Of Rheumatology 122

Jun 06, 2016: Five-year Results from Phase 3 Study of Jakafi (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis 123

Jun 02, 2016: AbbVie To present Data on ABT-494 at the Annual European Congress of Rheumatology 124

Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings 125

May 25, 2016: FITZROY Phase 2 study with filgotinib in Crohns Disease presented as late breaker at DDW 2016 126

May 24, 2016: Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA) 126

May 19, 2016: Incyte Highlights Jakafi (ruxolitinib) Abstract to be Presented at the 2016 ASCO and EHA Annual Meetings 127

May 19, 2016: Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata 128

May 04, 2016: Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata 129

May 03, 2016: Parkinson's disease pathogenesis reduced in rat model by a cell-signaling inhibitor drug 129

Appendix 132

Methodology 132

Coverage 132

Secondary Research 132

Primary Research 132

Expert Panel Validation 132

Contact Us 132

Disclaimer 133

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Products under Development by Companies, H2 2016 (Contd..3) 21

Products under Development by Companies, H2 2016 (Contd..4) 22

Products under Development by Companies, H2 2016 (Contd..5) 23

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 28

Pipeline by AbbVie Inc., H2 2016 29

Pipeline by Aclaris Therapeutics, Inc., H2 2016 30

Pipeline by Advinus Therapeutics Ltd, H2 2016 31

Pipeline by Astellas Pharma Inc., H2 2016 32

Pipeline by AstraZeneca Plc, H2 2016 33

Pipeline by Chipscreen Biosciences Ltd, H2 2016 34

Pipeline by CJ HealthCare Corp., H2 2016 35

Pipeline by Concert Pharmaceuticals, Inc., H2 2016 36

Pipeline by Eli Lilly and Company, H2 2016 37

Pipeline by Galapagos NV, H2 2016 38

Pipeline by Gilead Sciences, Inc., H2 2016 39

Pipeline by Incyte Corporation, H2 2016 40

Pipeline by Nissan Chemical Industries, Ltd., H2 2016 42

Pipeline by Pfizer Inc., H2 2016 43

Pipeline by Portola Pharmaceuticals, Inc., H2 2016 44

Pipeline by Sareum Holdings Plc, H2 2016 45

Pipeline by Theravance Biopharma, Inc., H2 2016 46

Pipeline by Vectura Group Plc, H2 2016 47

Dormant Projects, H2 2016 113

Dormant Projects (Contd..1), H2 2016 114

Discontinued Products, H2 2016 115

Discontinued Products (Contd..1), H2 2016 116

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports